Entering text into the input field will update the search result below

Biotech Forum Daily Digest For March 7th

Mar. 07, 2018 9:33 AM ETCLSD, DERM-OLD, ESPR, FATE, PTGX, TTOO, TTPH27 Comments


  • Fears of a 'trade war' and a key departure from the current administration should put the market in a 'risk off' mode today, at least in early going.
  • Dermira implodes on a key Phase III trial failure. Clearside Biomedical and Tetraphase Pharmaceuticals get several positive mentions from analysts.
  • All the other notable news, events and analyst ratings from across the sector as well as a Spotlight feature on T2 Biosystems are below.

Love all, trust a few, do wrong to none.” ― William Shakespeare

The choppy nature of the market continues. After posting slight gains on Tuesday, the main biotech indices will open substantially down today as will the rest of the overall market.

Today's rally killer is the departure of Gary Cohn from the White House. Mr. Cohn was a key economic adviser and driver of the recently passed tax reform package. As importantly, his departure will weakened the free trade wing within the administration and makes a feared 'trade war' more likely in coming months. Not something that is going down well with investors.

Author's note: To get these Biotech Forum Daily Digests as soon as they are published, just click here on my profile, hit the big orange "Follow" button, and choose the "real-time alerts" option

Dermira (DERM) was the big loser in the sector on Monday. The shares lost over 60% of their value after the company announced that its Phase 3 trial for its compound olumacostat glasaretil or DRM01 failed to meet all co-primary endpoints in its two pivotal trials for the treatment of moderate-to-severe acne vulgaris. Dermira will not discontinue development for this program. The company does have another compound 'DRM04' that has a PDUFA date late in June to treat primary axillary hyperhidrosis.

Esperion Therapeutics (ESPR) should buck the downward tilt of the market today and get a decent lift from trial results it announced this morning. The company discloses that a Phase 3 trial for its bempedoic acid in statin-intolerant patients atherosclerotic cardiovascular disease or at high risk of ASCVD with elevated low-density lipoprotein cholesterol met its primary endpoint.

Protagonist Therapeutics (PTGX) rallied some five percent in trading on Tuesday. Its compound PTG-300 was designated as an Orphan Drug by the FDA for

This article was written by

Bret Jensen profile picture
Finding tomorrow's big winners in the lucrative biotech sector

Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha. It is the fourth most subscribed to investment service offered through the Marketplace on SeekingAlpha.com. Our service offers a model-20 stock portfolio as well as the most active Live Chat on the Marketplace. This is where scores of seasoned biotech investors trade news and investment ideas back and forth throughout the trading day.

• • •

Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.

• • •

Learn more about Bret Jensen's Marketplace Offerings:

The Insiders Forum | The Biotech Forum | Busted IPO Forum

Analyst’s Disclosure: I am/we are long derm, fate, ttoo, ttph. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.